Director, Vasculitis and Scleroderma Program Department of Medicine, Division of Rheumatology, Hospital for Special Surgery.
Professor of Clinical Medicine at the Weill Cornell Medical College and Director of the Scleroderma and Vasculitis Center at the Hospital for Special Surgery where I am an Attending Physician. I spend my time both in the care of patients with complicated rheumatic diseases, mostly focusing on vasculitis and scleroderma, as well as clinical and translational investigation in those disorders. I have been a site PI on several multicenter NIH and industry-funded trials in vasculitis, including the RAVE and WGET trials in ANCA-associated vasculitis. I have also been a primary investigator in a number of investigator-initiated clinical trials, including an ongoing single site trial of Tocilizumab in polymyalgia rheumatica here at the Hospital for Special Surgery, and a single center trial here at HSS of methotrexate in Giant Cell Arteritis. I have also worked in Scleroderma where I have been the PI on a number of investigators initiated single center trials, lead investigator on a recently completed industry-sponsored multi-center controlled U.S. based clinical trial, and lead investigator for an international multi-center industry sponsored clinical trial. I have also served as site PI on numerous multi-center NIH and industry-funded trials I have been involved in translational investigations in systemic sclerosis, collaborating with investigators here at HSS (Franck Barrat, Theresa Lu, Allessandra Pernis and Mary Crow), but often needing to partner with investigators at outside institutions (including Stanford, BU, Dartmouth and Northwestern) who have helped with analyses of gene expression and other proteomics utilizing the biological specimens obtained in the course of our single site investigator initiated clinical trials of novel therapies in systemic sclerosis. We have specimens (serum, plasma, RNA and DNA, as well as skin biopsies) coupled with meticulously collected clinical data from over 60 patients enrolled in these trials over the past seven years. Such efforts are ongoing, as are anticipated new trials in the next two years.